Last reviewed · How we verify
FOLFOX regimen
FOLFOX is a chemotherapy combination regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms.
FOLFOX is a chemotherapy combination regimen that kills cancer cells by damaging DNA and preventing cell division through multiple mechanisms. Used for Metastatic colorectal cancer, Adjuvant treatment of stage III colon cancer, Gastric cancer.
At a glance
| Generic name | FOLFOX regimen |
|---|---|
| Also known as | Leucovorin, fluorouracil, and oxaliplatin, Physician Choice FOLFOX4, XELOX, FOLFOX, Leucovorin, Fluorouracil and Oxaliplatin |
| Sponsor | MIPO Clinic |
| Drug class | Chemotherapy combination regimen |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
FOLFOX combines three drugs: 5-fluorouracil (5-FU), which inhibits thymidylate synthase and disrupts DNA synthesis; leucovorin (folinic acid), which enhances 5-FU activity; and oxaliplatin, a platinum agent that forms DNA crosslinks. Together, these agents work synergistically to induce apoptosis in rapidly dividing cancer cells, particularly colorectal cancer cells.
Approved indications
- Metastatic colorectal cancer
- Adjuvant treatment of stage III colon cancer
- Gastric cancer
- Pancreatic cancer
Common side effects
- Neutropenia
- Peripheral neuropathy
- Nausea and vomiting
- Diarrhea
- Anemia
- Thrombocytopenia
- Mucositis
- Fatigue
Key clinical trials
- Study of Chemotherapy, With or Without Binimetinib in Advanced Biliary Tract Cancers in 2nd Line Setting (A ComboMATCH Treatment Trial) (PHASE2)
- Clinical Trial of an Anti-cancer Drug, CA-4948 (Emavusertib), in Combination With Chemotherapy Treatment (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer (PHASE1)
- HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer (NA)
- A Study to Evaluate the Adverse Events, Efficacy, and Optimal Dose of Intravenous (IV) ABBV-400 in Combination With IV Fluorouracil, Leucovorin, and Budigalimab in Adult Participants With Locally Advanced Unresectable or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (PHASE2)
- A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer (PHASE2, PHASE3)
- Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas (PHASE3)
- Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays (NA)
- A Study to Assess Intravenous (IV) Telisotuzumab Adizutecan in Combination With Fluorouracil, Folinic Acid, and Oxaliplatin (FOLFOX) Compared to Standard of Care in Adult Participants With First-Line Metastatic Pancreatic Ductal Adenocarcinoma (PHASE2, PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |